This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Envista (NVST) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Envista (NVST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Envista (NVST) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Envista (NVST) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Hold on to Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) owing to its progress with its three-legged strategic, which is driving growth and an impressive 2025 roadmap.
Cardiovascular Systems (CSII) Inks Deal to Enhance Patient Care
by Zacks Equity Research
Cardiovascular Systems' (CSII) investment in CarePICS will advance patient access to the suitable treatment at the right time, thereby leading to improved care and reduced amputations.
Envista (NVST) Soars 6.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Envista (NVST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CVS Health (CVS) Extends COVID-19 Antibody Testing Nationwide
by Zacks Equity Research
CVS Health's (CVS) antibody test detects for previous infection to COVID-19 and provides results within 15 minutes.
NuVasive's (NUVA) Simply Cervical Artificial Disc Gets FDA Nod
by Zacks Equity Research
NuVasive's (NUVA) Simplify Disc demonstrated an overall clinical success rate nearly 10% higher than the anterior cervical discectomy and fusion.
Medtronic (MDT) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Medtronic's (MDT) ventilator sales are robust and prospects of the Diabetes arm remain strong amid the pandemic.
Abbott's (ABT) DAPT for High Bleeding Risk Gets Europe Nod
by Zacks Equity Research
The studies by Abbott (ABT) show that DAPT can be safely discontinued early with no increased risk in patient adverse events.
Here's Why You Should Retain Abbott Laboratories (ABT) Stock
by Zacks Equity Research
Investors remain optimistic about Abbott Laboratories (ABT) owing to strong growth in its molecular and rapid diagnostics business and progress in diabetes arm.
Abbott's (ABT) BinaxNOW Test Gets FDA's EUA for Self Use
by Zacks Equity Research
According to Abbott (ABT), the self-test BinaxNOW together with vaccines will help Americans get back to their regular daily work with greater confidence.
Syneos Health (SYNH) New Partnership to Enhance Clinical Trials
by Zacks Equity Research
Syneos Health (SYNH) new partnership will extend the company's mission to boost research and enable universal patient and provider access with clinical research services.
Here's Why You Should Add Haemonetics (HAE) to Your Portfolio
by Zacks Equity Research
Investor are optimistic about Haemonetics (HAE) on its continued Plasma franchise growth and huge potential of Hemostasis Management franchise.
Abbott (ABT) Nutrition Shows Robust Momentum Amid Pandemic
by Zacks Equity Research
Within Medical Device, Abbott (ABT) Diabetes Care business has been in the limelight for developments in its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Cardiovascular Systems' (CSII) New Buyout Boosts CAD/PAD Line
by Zacks Equity Research
Cardiovascular Systems' (CSII) acquisition of Peripheral Support Catheters will enhance outcomes for patients undergoing complex peripheral and coronary interventions.
IDEXX (IDXX) CAG Placement Grows Sequentially Amid COVID-19 Woes
by Zacks Equity Research
IDEXX's (IDXX) Global Reference Lab revenues are growing organically in the United States and in international markets.
Insulet's (PODD) Omnipod 5 Pivotal Trial Outcome Favorable
by Zacks Equity Research
Insulet's (PODD) Omnipod 5 pivotal study showed improvement in glucose control, verified by notable reduction in HbA1c and enhanced time in range together with the lowest rates of hypoglycemia.
NuVasive (NUVA) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
NuVasive (NUVA) is optimistic about its strong international performance and a huge growth potential in the spine market.
Penumbra (PEN) Launches INDIGO System Lightning 7 in US
by Zacks Equity Research
Penumbra's (PEN) INDIGO System Lightning 7 assists physicians in easing arterial thrombus removal with single-session results.
Cardiovascular Systems' (CSII) WIRION Cures 1st U.S Patient
by Zacks Equity Research
Cardiovascular Systems' (CSII) WIRION demonstrated a major adverse event rate of 1.9%, which is lower than the earlier reported rates for other lower extremity embolic protection filters.
Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Bio-Rad (BIO) backed by strong segmental performance across geographies and robust testing portfolio.
Abbott's (ABT) Diagnostics Arm to Gain From New & Updated EUAs
by Zacks Equity Research
Abbott's (ABT) Alinity m SARS-CoV-2 test set to detect COVID-19 in individuals who do not have symptoms.
Boston Scientific (BSX) Buys Lumenis to Expand in Urology
by Zacks Equity Research
The transaction is expected to remain immaterial to Boston Scientific's (BSX) 2021 adjusted earnings per share.
Abbott (ABT) Gets Canadian Nod for FreeStyle Libre Expanded Use
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre is the only glucose sensing technology available in Canada to remotely monitor glucose status in an expectant mother to reduce exposure to COVID-19.
Omnicell (OMCL) Grows on New Services Amid Pandemic Woes
by Zacks Equity Research
Omnicell (OMCL) is progressing in autonomous pharmacy space by expanding portfolio and investing in the digital cloud-based platform.